Greenhouse Gas Emissions from Respiratory Treatments: Results from the SABA CARBON International Study
Journal
Advances in therapy
Journal Volume
40
Journal Issue
11
Date Issued
2023-11
Author(s)
Alzaabi, Ashraf
Bell, John P
Montero-Arias, Felicia
Price, David B
Jackson, David J
Budgen, Nigel
Farouk, Hisham
Maslova, Ekaterina
Abstract
Healthcare systems are looking to reduce their carbon impact. Short-acting β2-agonist (SABA) overuse (≥ 3 canisters/year) is common in asthma and linked to poor outcomes; however, its environmental impact remains unknown. As part of the CARBON programme, this study retrospectively quantified the carbon footprint of SABA and controller inhalers across all respiratory indications and SABA overuse in asthma in lower-middle-income countries (LMICs), upper-middle-income countries and high-income countries across Africa, Asia Pacific, Latin America and the Middle East.
Subjects
Asthma; Asthma control; Carbon footprint; Environmental monitoring; Greenhouse gas emissions; Inhaler therapies; Inhalers; SABA; Short-acting β2-agonist
Type
journal article